Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLFM4 in High-Risk Breast Cancer Screening
NCT02653105Active, not recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Mar 2016
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Predictive value of circulating OLFM4 in BRCA1/2 mutation carriers or high-risk women with positive breast imaging at 10 years. Started Mar 2016; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02653105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653105.